Peptides selectively lethal to malignant and transformed mammalian cells
The present invention provides peptides corresponding to all or a portion of amino acid residues 12-26 of human p53 protein. When fused to a leader sequence which penetrates the membrane, the peptides are either lethal to malignant or transformed cells or cause morphological reversion untransformed phenotype. The peptides are thus useful in the treatment of neoplastic disease in an animal, preferably a human. Pharmaceutical compositions comprising the subject peptides in admixture with a pharmaceutically acceptable carrier are also provided. Methods of treatment of neoplastic disease are also provided in a patient by administering a subject peptide.